Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event …
J Zhang, T Qiu, Y Zhou, S Wu… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Background Interstitial lung disease (ILD) was a relatively common cause of drug-induced
mortality. However, the safety profile of the whole TKIs induced ILD was largely unknown …
mortality. However, the safety profile of the whole TKIs induced ILD was largely unknown …
Hepatotoxicity of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)
L Zhu, X Yang, S Wu, R Dong, Y Yan, N Lin… - Drug Metabolism …, 2024 - Taylor & Francis
Drug-induced liver injury (DILI) is one of the most frequently adverse reactions in clinical
drug use, usually caused by drugs or herbal compounds. Compared with other populations …
drug use, usually caused by drugs or herbal compounds. Compared with other populations …
Nimotuzumab for COVID-19: case series
AA Abdo Cuza, J Pi Avila, R Machado Martinez… - …, 2022 - Taylor & Francis
Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells.
EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR …
EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR …
Interstitial pneumonitis associated with EGFR/ALK tyrosine kinase inhibitors used in non–small cell lung cancer: an observational, retrospective, pharmacovigilance …
Z Ma, J Pei, Y Zhang, H Li, D Sun… - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Background Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase
Tyrosine kinase inhibitors (EGFR/ALK TKIs) may provoke fatal interstitial pneumonitis (IP) …
Tyrosine kinase inhibitors (EGFR/ALK TKIs) may provoke fatal interstitial pneumonitis (IP) …
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Q Zhou, Z Hu, X Li, X Tang - BMC Pulmonary Medicine, 2023 - Springer
Background With the use of targeted drugs in lung cancer patients, targeted drug-induced
interstitial lung disease (ILD) has attracted more and more attention. The incidence, time …
interstitial lung disease (ILD) has attracted more and more attention. The incidence, time …
Cancer treatments as paradoxical catalysts of tumor awakening in the lung
E Nicolas, B Kosmider, E Cukierman… - Cancer and Metastasis …, 2024 - Springer
Much of the fatality of tumors is linked to the growth of metastases, which can emerge
months to years after apparently successful treatment of primary tumors. Metastases arise …
months to years after apparently successful treatment of primary tumors. Metastases arise …
Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS …
N Kanaji, E Ichihara, T Tanaka, T Ninomiya, T Kozuki… - lung, 2024 - Springer
Purpose This study investigated the safety and efficacy of epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI …
(EGFR)-tyrosine kinase inhibitor (TKI) re-administration after recovery from EGFR-TKI …
Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection
F Perrotta, V Chino, V Allocca, V D'Agnano… - Expert Review of …, 2022 - Taylor & Francis
Introduction Many data already suggested that cancer and IPF are underlined by a number
of common pathogenic biologic pathways. However, fewer data regards the …
of common pathogenic biologic pathways. However, fewer data regards the …
Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer
M Velimirovic, M Brignola, E Chheng, M Smith… - … Treatment Options in …, 2024 - Springer
Opinion Statement Drug-induced pneumonitis is a common adverse event that may occur
during lung cancer systemic therapy. The incidence/prevalence of this side effect has …
during lung cancer systemic therapy. The incidence/prevalence of this side effect has …
[HTML][HTML] Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
WA Alanazi, HN Alhamami, AA Alshamrani… - Saudi Journal of …, 2023 - Elsevier
Gefitinib (GEF) is an inhibitor of the epidermal growth factor receptor, linked to higher risk of
severe/fatal interstitial lung disease (ILD). This study was performed to determine the …
severe/fatal interstitial lung disease (ILD). This study was performed to determine the …